Patients with previously treated colorectal cancer that has spread only to the liver may be eligible to participate in a new clinical trial at the NIH Clinical Center.
A class of immunotherapy drugs called immune checkpoint inhibitors is increasingly being used to treat a wide range of cancers, but they seem to be more effective in some patients more than others.
A first-in-human trial evaluating an experimental treatment for Ebola virus disease has begun at the National Institutes of Health Clinical Center in Bethesda, Maryland.
A first-in-human trial evaluating an experimental treatment for Ebola virus disease has begun at the National Institutes of Health Clinical Center in Bethesda, Maryland.
Mulcahy was diagnosed with merkel cell carcinoma (MCC) in September of 2016. MCC is a rare, aggressive form of skin cancer in which merkel cells found in the top layer of skin grow out of control to form painless lumps.
The Tomosynthesis Mammographic Imaging Screening Trial (TMIST), the first randomized trial to compare two types of digital mammography for breast cancer screening, is now open for enrollment.
The National Heart, Lung, and Blood Institute and the National Institute of Allergy and Infectious Diseases launched the REPRIEVE trial to determine whether a daily dose of a cholesterol-lowering statin can reduce the risk of cardiovascular disease in people living with HIV who would not normally be prescribed a statin.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched a Phase 1 clinical trial to test an investigational vaccine intended to provide broad protection against a range of mosquito-transmitted diseases, such as Zika, malaria, West Nile fever and dengue fever, and to hinder the ability of mosquitoes to transmit such infections.
More than 6,500 rare diseases affect humans, of which only a few hundred have any treatment. In total these illnesses affect an estimated 25 million people in the United States.
This one-page guide describes different kinds of clinical studies. It explains why researchers might use them and highlights each type’s strengths and weaknesses.
Ever since being diagnosed in January of ’14, I kind of made it a mission of mine to find out as much as I can, what’s available out there as treatments, trials, and just my way of giving back, whether it helps me directly or somebody who comes after me.
Dr. Madhav Thambisetty of the National Institute on Aging at NIH discusses the role of study partners in Alzheimer's disease clinical trials. A study partner relates her experience in an Alzheimer's trial.
